



August 23 2019

Dear all concerned

2148-188 Nishiminowa, Ina-shi, Nagano-ken  
399-4501, Japan  
Ina Research Inc.  
Kenshi Nakagawa, President & CEO  
(TSE Code : 2176)  
Contact : Fumihiko Notake, Operating Officer  
Phone: +81- 265-72- 6616

**Announcement concerning the start of agency business**  
**with ViruSure**

Ina Research Inc. (hereinafter referred to as “our company”) is pleased to announce that our company has decided to start the agency business for ViruSure (Austria : hereinafter referred to as “VS”), which is a contract research organization (hereinafter referred to as “CRO” ) in Japan and Taiwan today.

**1 . Feature of Austria VS**

For biologics such as vaccines, blood products, antibody / nucleic acid drugs, and regenerative medicine products, it is obliged to submit the results of virus testing or genetic stability when applying for regulatory approval.

VS is a CRO that mainly conducts virus safety tests and other biosafety tests related to CMC (quality evaluation of pharmaceutical products) for these biologics.

VS has already established a strong relationship with major vaccine and blood product related companies in Japan, and is expected to expand its business in the field of regenerative medicine.

The profile of VS is as follows. Neither has any capital relationship, personal relationships, trading relations to date. There are no relevant parties.

**Austria VS**

( 1 ) Name	VirusSure GmbH
( 2 ) Address	Tech Gate Science & Technology Park, Donau City Strasse 1, A-1220, Vienna, Austria
( 3 ) Title and name of the representative	Andy Bailey, Ph.D., Operations Director & Founder
( 4 ) Business contents	CRO specializing in virus safety and biosafety testing of biologics. VS has more than 150 customers around the world.
( 5 ) Established Year	2005

## **2 . Agency business start date**

**Start from August 23, 2019**

## **3 . Future prospects and impact on our company business performance**

The CMC field covers not only non-clinical studies but also clinical studies and post-marketing, contributing to the expansion of our business fields. In addition, we can expect a complementary effect on the same customers as the test system owned by Southern Research in the United States, where we have signed an agency contract in January 2019. The impact on the Company's business performance for the fiscal year ending March 2020 is expected to be minor, but we will promptly notify you if it is found that it will affect the future business performance.

that's all